Use of biologic response modifiers for the management of ocular inflammatory conditions

Erick Rivera-Grana, Jay Siak, James (Jim) Rosenbaum

Research output: Contribution to journalReview article

Abstract

Ocular inflammatory conditions can be challenging to manage due to their prolonged and complicated nature. While the mainstay treatment for most cases is oral or topical corticosteroids, it is very important that physicians know how other medications such as biologic response modifiers (biologics) could be used in certain cases. Through illustrative cases, we discuss how treatment with biologics can be helpful in the management of three challenging patients with ocular inflammatory conditions. We review and discuss, (1) a 60-year-old male with granulomatosis with polyangiitis and bilateral anterior scleritis who required rituximab; (2) a 25-year-old male with refractory, idiopathic, bilateral chronic panuveitis and retinal vasculitis, which was controlled with adalimumab after treatment failure with oral and topical corticosteroids, cyclosporine, and methotrexate; and (3) a 44-year-old female with unilateral blindness and juvenile psoriatic arthritis-related intermediate uveitis, who required adalimumab to control her complication of persistent macular edema. These cases highlight the considerations that are required when clinicians are faced with the need to commence biologic therapy for patients with refractory ocular inflammation.

Original languageEnglish (US)
Pages (from-to)259-263
Number of pages5
JournalIndian Journal of Rheumatology
Volume13
Issue number4
DOIs
StatePublished - Dec 1 2018

Fingerprint

Biological Products
Adrenal Cortex Hormones
Intermediate Uveitis
Panuveitis
Retinal Vasculitis
Scleritis
Granulomatosis with Polyangiitis
Biological Therapy
Macular Edema
Juvenile Arthritis
Blindness
Treatment Failure
Methotrexate
Cyclosporine
Inflammation
Physicians
Therapeutics
Adalimumab
Rituximab

Keywords

  • Biologics
  • scleritis
  • uveitis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Use of biologic response modifiers for the management of ocular inflammatory conditions. / Rivera-Grana, Erick; Siak, Jay; Rosenbaum, James (Jim).

In: Indian Journal of Rheumatology, Vol. 13, No. 4, 01.12.2018, p. 259-263.

Research output: Contribution to journalReview article

@article{99f95dc6c44d4d76a15b592164640326,
title = "Use of biologic response modifiers for the management of ocular inflammatory conditions",
abstract = "Ocular inflammatory conditions can be challenging to manage due to their prolonged and complicated nature. While the mainstay treatment for most cases is oral or topical corticosteroids, it is very important that physicians know how other medications such as biologic response modifiers (biologics) could be used in certain cases. Through illustrative cases, we discuss how treatment with biologics can be helpful in the management of three challenging patients with ocular inflammatory conditions. We review and discuss, (1) a 60-year-old male with granulomatosis with polyangiitis and bilateral anterior scleritis who required rituximab; (2) a 25-year-old male with refractory, idiopathic, bilateral chronic panuveitis and retinal vasculitis, which was controlled with adalimumab after treatment failure with oral and topical corticosteroids, cyclosporine, and methotrexate; and (3) a 44-year-old female with unilateral blindness and juvenile psoriatic arthritis-related intermediate uveitis, who required adalimumab to control her complication of persistent macular edema. These cases highlight the considerations that are required when clinicians are faced with the need to commence biologic therapy for patients with refractory ocular inflammation.",
keywords = "Biologics, scleritis, uveitis",
author = "Erick Rivera-Grana and Jay Siak and Rosenbaum, {James (Jim)}",
year = "2018",
month = "12",
day = "1",
doi = "10.4103/injr.injr_83_18",
language = "English (US)",
volume = "13",
pages = "259--263",
journal = "Indian Journal of Rheumatology",
issn = "0973-3698",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "4",

}

TY - JOUR

T1 - Use of biologic response modifiers for the management of ocular inflammatory conditions

AU - Rivera-Grana, Erick

AU - Siak, Jay

AU - Rosenbaum, James (Jim)

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Ocular inflammatory conditions can be challenging to manage due to their prolonged and complicated nature. While the mainstay treatment for most cases is oral or topical corticosteroids, it is very important that physicians know how other medications such as biologic response modifiers (biologics) could be used in certain cases. Through illustrative cases, we discuss how treatment with biologics can be helpful in the management of three challenging patients with ocular inflammatory conditions. We review and discuss, (1) a 60-year-old male with granulomatosis with polyangiitis and bilateral anterior scleritis who required rituximab; (2) a 25-year-old male with refractory, idiopathic, bilateral chronic panuveitis and retinal vasculitis, which was controlled with adalimumab after treatment failure with oral and topical corticosteroids, cyclosporine, and methotrexate; and (3) a 44-year-old female with unilateral blindness and juvenile psoriatic arthritis-related intermediate uveitis, who required adalimumab to control her complication of persistent macular edema. These cases highlight the considerations that are required when clinicians are faced with the need to commence biologic therapy for patients with refractory ocular inflammation.

AB - Ocular inflammatory conditions can be challenging to manage due to their prolonged and complicated nature. While the mainstay treatment for most cases is oral or topical corticosteroids, it is very important that physicians know how other medications such as biologic response modifiers (biologics) could be used in certain cases. Through illustrative cases, we discuss how treatment with biologics can be helpful in the management of three challenging patients with ocular inflammatory conditions. We review and discuss, (1) a 60-year-old male with granulomatosis with polyangiitis and bilateral anterior scleritis who required rituximab; (2) a 25-year-old male with refractory, idiopathic, bilateral chronic panuveitis and retinal vasculitis, which was controlled with adalimumab after treatment failure with oral and topical corticosteroids, cyclosporine, and methotrexate; and (3) a 44-year-old female with unilateral blindness and juvenile psoriatic arthritis-related intermediate uveitis, who required adalimumab to control her complication of persistent macular edema. These cases highlight the considerations that are required when clinicians are faced with the need to commence biologic therapy for patients with refractory ocular inflammation.

KW - Biologics

KW - scleritis

KW - uveitis

UR - http://www.scopus.com/inward/record.url?scp=85057213208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057213208&partnerID=8YFLogxK

U2 - 10.4103/injr.injr_83_18

DO - 10.4103/injr.injr_83_18

M3 - Review article

AN - SCOPUS:85057213208

VL - 13

SP - 259

EP - 263

JO - Indian Journal of Rheumatology

JF - Indian Journal of Rheumatology

SN - 0973-3698

IS - 4

ER -